Search hospitals > British Columbia > VANCOUVER
University of British Columbia
Claim this profileVANCOUVER, British Columbia V6T 1Z4
Global Leader in Alzheimer's Disease
Global Leader in Depression
Conducts research for Motor Skills
Conducts research for Major Depressive Disorder
Conducts research for Stroke
213 reported clinical trials
18 medical researchers
Summary
University of British Columbia is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Alzheimer's Disease, Depression, Motor Skills, Major Depressive Disorder, Stroke and other specialties. University of British Columbia is involved with conducting 213 clinical trials across 432 conditions. There are 18 research doctors associated with this hospital, such as Robin Hsiung, MD, Fidel Vila-Rodriguez, MD, PhD, Andrei Krassioukov, MD,PhD,FRCPC, and Raymond W Lam, MD.Area of expertise
1Alzheimer's Disease
Global LeaderAPP positive
PSEN2 positive
PSEN1 positive
2Depression
Global LeaderTop PIs
Robin Hsiung, MDUBC Hospital7 years of reported clinical research
Studies Alzheimer's Disease
Studies Dementia
10 reported clinical trials
16 drugs studied
Fidel Vila-Rodriguez, MD, PhDUniversity of British Columbia7 years of reported clinical research
Studies Depression
Studies Major Depressive Disorder
8 reported clinical trials
13 drugs studied
Andrei Krassioukov, MD,PhD,FRCPCBlusson Spinal Cord Centre3 years of reported clinical research
Studies Spinal Cord Injury
Studies Neurogenic Bladder
7 reported clinical trials
11 drugs studied
Raymond W Lam, MDUniversity of British Columbia5 years of reported clinical research
Studies Depression
Studies Major Depressive Disorder
4 reported clinical trials
4 drugs studied
Clinical Trials running at University of British Columbia
Alzheimer's Disease
Depression
Cancer
Prostate Cancer
Huntington's Disease
Schizophrenia
Dementia
Asthma
Traumatic Brain Injury
Amyloidosis
Acoramidis
for Amyloidosis
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Recruiting1 award Phase 33 criteria
Gantenerumab
for Alzheimer's Disease
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Remternetug
for Alzheimer's Disease
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting0 awards Phase 2 & 32 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of British Columbia?
University of British Columbia is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Alzheimer's Disease, Depression, Motor Skills, Major Depressive Disorder, Stroke and other specialties. University of British Columbia is involved with conducting 213 clinical trials across 432 conditions. There are 18 research doctors associated with this hospital, such as Robin Hsiung, MD, Fidel Vila-Rodriguez, MD, PhD, Andrei Krassioukov, MD,PhD,FRCPC, and Raymond W Lam, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.